Núcleo de Pesquisa em Farmacogenômica e Diagnóstico Molecular

Linhas de pesquisa com interface com a REFARGEN:

• Biomarcadores moleculares e fisiopatologia
• Farmacogenômica & farmacogenética
• Tecnologia aplicada ao diagnóstico molecular e farmacogenética

Publicações selecionadas

1. Lima-Neto LG, Hirata RD, Luchessi AD, Silbiger VN, Stephano MA, Sampaio MF, Armaganijan D, Hirata MH. CD14 and IL6 polymorphisms are associated with a pro-atherogenic profile in young adults with acute myocardial infarction. J Thromb Thrombolysis. 2012 Nov 8. [Epub ahead of print].
2. Rodrigues AC, Sobrino B, Genvigir FD, Willrich MA, Arazi SS, Dorea EL, Bernik MM, Bertolami M, Faludi AA, Brion MJ, Carracedo A, Hirata MH, Hirata RD. Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response. Clin Chim Acta. 2013 Feb 18;417:8-11.
3. Forestiero FJ, Cecon L, Hirata MH, de Melo FF, Cardoso RF, Cerda A, Hirata RD. Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy. Clin Chim Acta. 2013 Jan 16;415:215-9.
4. Nogueira LG, Santos RH, Ianni BM, Fiorelli AI, Mairena EC, Benvenuti LA, Frade A, Donadi E, Dias F, Saba B, Wang HT, Fragata A, Sampaio M, Hirata MH, Buck P, Mady C, Bocchi EA, Stolf NA, Kalil J, Cunha-Neto E. yocardial chemokine expression and intensity of myocarditis in Chagas cardiomyopathy are controlled by polymorphisms in CXCL9 and CXCL10. PLoS Negl Trop Dis. 2012 Oct;6(10):e1867.
5. Luchessi AD, Silbiger VN, Cerda A, Hirata RD, Carracedo A, Brion M, Iñiguez A, Bravo M, Bastos G, Sousa AG, Hirata MH. Increased clopidogrel response is associated with ABCC3 expression: a pilot study. Clin Chim Acta. 2012 Feb 18;413(3-4):417-21.
6. Hinuy HM, Arazi SS, Hirata MH, Sampaio MF, Armaganijan D, Cavalli SA, Hirata RD. elationship of short tandem repeats flanking leptin-melanocortin pathway genes with anthropometric profile and leptinemia in Brazilian individuals. Arq Bras Endocrinol Metabol. 2012 Feb;56(1):47-53.
7. Issa MH, Cerda A, Genvigir FD, Cavalli SA, Bertolami MC, Faludi AA, Hirata MH, Hirata RD. Atorvastatin and hormone therapy effects on APOE mRNA expression in hypercholesterolemic postmenopausal women. J Steroid Biochem Mol Biol. 2012 Feb;128(3-5):139-44.
8. Cerda A, Genvigir FD, Willrich MA, Arazi SS, Bernik MM, Dorea EL, Bertolami MC, Faludi AA, Hirata MH, Hirata RD. Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin. Lipids Health Dis. 2011 Nov 10;10:206.
9. Rodrigues AC, Perin PM, Purim SG, Silbiger VN, Genvigir FD, Willrich MA, Arazi SS, Luchessi AD, Hirata MH, Bernik MM, Dorea EL, Santos C, Faludi AA, Bertolami MC, Salas A, Freire A, Lareu MV, Phillips C, Porras-Hurtado L, Fondevila M, Carracedo A, Hirata RD. Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response. Int J Mol Sci. 2011;12(9):5815-27.
10. Cerda Á, Genvigir FD, Rodrigues AC, Willrich MA, Dorea EL, Bernik MM, Arazi SS, Oliveira Rd, Hirata MH, Hirata RD. Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression. J Atheroscler Thromb. 2011;18(8):640-51.